Multipotent Adult Stem Cells And Uses of Multipotent Adult Stem Cells To Treat Inflammation

Abstract

Disclosed are cell preparations comprising multipotent adult stem cells and methods for using multipotent adult stem cells to treat autoimmune diseases, treat allergic responses, treat cancer, treat inflammatory diseases, treat fibrotic disorders, reduce inflammation and/or fibrosis, promote would healing, repair epithelial damage, and/or promote angiogenesis.

1 . A cell preparation comprising adult bone marrow-derived stem cells in a dose effective to treat an inflammatory response in a subject. 
     
     
         2 . The cell preparation of  claim 1 , wherein the stem cells are capable of differentiating into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages. 
     
     
         3 . The cell preparation of  claim 1 , wherein the stem cells are capable of differentiating into at least one cell type of at least one of the endodermal, ectodermal, or mesodermal embryonic lineages. 
     
     
         4 . The cell preparation of  claim 1 , wherein the dose contains a sufficient number of stem cells to provide about 1×10 5  to about 1×10 7  cells per kilogram of the subject. 
     
     
         5 . The cell preparation of  claim 1 , wherein the stem cells are positive for one or more cell surface markers selected from the group consisting of integrin al (CD49a); integrin α2 (CD49b); integrin α3 (CD49c); integrin α5 (CD49e); integrin αV (CD51); integrin β1 (CD29); integrin β3 (CD61); integrin β4 (CD104); IL-1R (CD121a); IL-3Rα (CD123); IL-4R (CDw124); IL-6R (CD126); IL-7R (CDw127); IFNγR (CDw119); TNFIR (CD120a); TNFIIR (CD120b); TGFβ1R; TGFβIIR; bFGFR; PDGFR (CD140a); transferrin (CD71); ICAM-1 (CD54); ICAM-2 (CD102); VCAM-1 (CD106); L-Selectin (CD62L); LFA-3 (CD58); ALCAM (CD166); hyaluronate (CD44); endoglin (CD105); Thy-1 (CD90); and CD9. 
     
     
         6 . The cell preparation of  claim 1 , wherein administration of the cell preparation elevates interferon-beta levels in the subject. 
     
     
         7 . The cell preparation of  claim 1 , wherein the subject is a subject having inflammatory bowel disease. 
     
     
         8 . A method of treating inflammatory bowel disease in a subject, comprising the step of:
 administering to the subject allogeneic, multipotent adult bone marrow-derived stem cells in an amount effective to treat the inflammatory bowel disease.   
     
     
         9 . The method of  claim 8 , wherein the multipotent stem cells are administered intravenously or intraarterially. 
     
     
         10 . The method of  claim 8 , wherein the multipotent stem cells are positive for one or more cell surface markers selected from the group consisting of integrin al (CD49a); integrin α2 (CD49b); integrin α3 (CD49c); integrin α5 (CD49e); integrin αV (CD51); integrin β1 (CD29); integrin β3 (CD61); integrin β4 (CD104); IL-1R (CD121a); IL-3Rα (CD123); IL-4R (CDw124); IL-6R (CD126); IL-7R (CDw127); IFNγR (CDw119); TNFIR (CD120a); TNFIIR (CD120b); TGFβ1R; TGFβIIR; bFGFR; PDGFR (CD140a); transferrin (CD71); ICAM-1 (CD54); ICAM-2 (CD102); VCAM-1 (CD106); L-Selectin (CD62L); LFA-3 (CD58); ALCAM (CD166); hyaluronate (CD44); endoglin (CD105); Thy-1 (CD90); and CD9. 
     
     
         11 . The method of  claim 8 , wherein the multipotent stem cells are positive for CD49b, CD49e, and CD140a. 
     
     
         12 . The method of  claim 8 , wherein the multipotent stem cells are negative for one or more cell surface markers selected from the group consisting of integrin α4 (CD49d); integrin αL (CD11a); integrin Cβ2 (CD18); CD4; CD14; CD34; CD45; IL-2R (CD25); EGFR-3; Fas ligand; ICAM-3 (CD50); E-Selectin (CD62E); P-Selectin (CD62P); vW Factor; cadherin 5; and Lewis x (CD15). 
     
     
         13 . The method of  claim 8 , wherein the multipotent stem cells are negative for CD34, CD45, CD62E, and CD62P. 
     
     
         14 . A method of treating a gastrointestinal autoimmune disease in a subject, comprising the step of:
 administering to the subject allogeneic multipotent adult stem cells in an amount effective to repair or regenerate intestinal tissue.   
     
     
         15 . The method of  claim 14 , wherein the autoimmune disease is selected from the group consisting of Crohn's disease, inflammatory bowel disease, and autoimmune gastritis. 
     
     
         16 . The method of  claim 14 , wherein the multipotent stem cells are administered intravenously or intraarterially. 
     
     
         17 . The method of  claim 14 , wherein the multipotent stem cells are positive for one or more cell surface markers selected from the group consisting of integrin al (CD49a); integrin α2 (CD49b); integrin α3 (CD49c); integrin α5 (CD49e); integrin αV (CD51); integrin β1 (CD29); integrin β3 (CD61); integrin β4 (CD104); IL-1R (CD121a); IL-3Rα (CD123); IL-4R (CDw124); IL-6R (CD126); IL-7R (CDw127); IFNγR (CDw119); TNFIR (CD120a); TNFIIR (CD120b); TGFβ1R; TGFβIIR; bFGFR; PDGFR (CD140a); transferrin (CD71); ICAM-1 (CD54); ICAM-2 (CD102); VCAM-1 (CD106); L-Selectin (CD62L); LFA-3 (CD58); ALCAM (CD166); hyaluronate (CD44); endoglin (CD105); Thy-1 (CD90); and CD9. 
     
     
         18 . The method of  claim 14 , wherein the multipotent stem cells are positive for CD49b, CD49e, and CD140a. 
     
     
         19 . The method of  claim 14 , wherein the multipotent stem cells are negative for one or more cell surface markers selected from the group consisting of integrin α4 (CD49d); integrin αL (CD11a); integrin Cβ2 (CD18); CD4; CD14; CD34; CD45; IL-2R (CD25); EGFR-3; Fas ligand; ICAM-3 (CD50); E-Selectin (CD62E); P-Selectin (CD62P); vW Factor; cadherin 5; and Lewis x (CD15). 
     
     
         20 . The method of  claim 14 , wherein the multipotent stem cells are negative for CD34, CD45, CD62E, and CD62P. 
     
     
         21 . A method of repairing or regenerating intestinal tissue in a human, comprising the step of:
 treating the human with allogeneic adult mesenchymal stem cells.   
     
     
         22 . The method of  claim 21 , wherein the mesenchymal stem cells are administered to the human. 
     
     
         23 . The method of  claim 22 , wherein the administration of the mesenchymal stem cell comprises intravenous, intraarterial, or intraperitoneal injection.